Abdul Malik Tyagi

List of Publications by Year
in descending order

29 papers	2,321 citations	257357 24 h-index	477173 29 g-index
30 all docs	30 docs citations	30 times ranked	2552 citing authors

#	Article	IF	Citations
1	The gut microbiota is a transmissible determinant of skeletal maturation. ELife, 2021, 10, .	2.8	25
2	Ovariectomy induces bone loss via microbial-dependent trafficking of intestinal TNF+ T cells and Th17 cells. Journal of Clinical Investigation, 2021, 131, .	3.9	54
3	PTH induces bone loss via microbial-dependent expansion of intestinal TNF+ T cells and Th17 cells. Nature Communications, 2020, 11, 468.	5.8	78
4	Parathyroid hormoneâ€“dependent bone formation requires butyrate production by intestinal microbiota. Journal of Clinical Investigation, 2020, 130, 1767-1781.	3.9	97
5	IL-17 Receptor Signaling in Osteoblasts/Osteocytes Mediates PTH-Induced Bone Loss and Enhances Osteocytic RANKL Production. Journal of Bone and Mineral Research, 2019, 34, 349-360.	3.1	47
6	Regulatory T cells are expanded by Teriparatide treatment in humans and mediate intermittent <scp>PTH</scp> â€induced bone anabolism in mice. EMBO Reports, 2018, 19, 156-171.	2.0	45
7	The Microbial Metabolite Butyrate Stimulates Bone Formation via T Regulatory Cell-Mediated Regulation of WNT10B Expression. Immunity, 2018, 49, 1116-1131.e7.	6.6	288
8	3-Piperidylethoxypterocarpan: A potential bone anabolic agent that improves bone quality and restores trabecular micro-architecture in ovariectomized osteopenic rats. Molecular and Cellular Endocrinology, 2017, 448, 41-54.	1.6	4
9	Molecular Mechanism of Rheumatic Diseases and Efficacy of Current Therapies. BioMed Research International, 2017, 2017, 1-2.	0.9	2
10	Methoxyisoflavones formononetin and isoformononetin inhibit the differentiation of Th17 cells and B-cell lymphopoesis to promote osteogenesis in estrogen-deficient bone loss conditions. Menopause, 2016, 23, 565-576.	0.8	24
11	Hydrogen Sulfide Is a Novel Regulator of Bone Formation Implicated in the Bone Loss Induced by Estrogen Deficiency. Journal of Bone and Mineral Research, 2016, 31, 949-963.	3.1	91
12	IL-18BP is decreased in osteoporotic women: Prevents Inflammasome mediated IL-18 activation and reduces Th17 differentiation. Scientific Reports, 2016, 6, 33680.	1.6	50
13	Sex steroid deficiencyâ€“associated bone loss is microbiota dependent and prevented by probiotics. Journal of Clinical Investigation, 2016, 126, 2049-2063.	3.9	416
14	T Cellâ€“Expressed CD40L Potentiates the Bone Anabolic Activity of Intermittent PTH Treatment. Journal of Bone and Mineral Research, 2015, 30, 695-705.	3.1	33
15	IL-17A Is Increased in Humans with Primary Hyperparathyroidism and Mediates PTH-Induced Bone Loss in Mice. Cell Metabolism, 2015, 22, 799-810.	7.2	82
16	miR-542-3p suppresses osteoblast cell proliferation and differentiation, targets BMP-7 signaling and inhibits bone formation. Cell Death and Disease, 2014, 5, e1050-e1050.	2.7	128
17	Enhanced Immunoprotective Effects by Anti-IL-17 Antibody Translates to Improved Skeletal Parameters Under Estrogen Deficiency Compared With Anti-RANKL and Anti-TNF-Î± Antibodies. Journal of Bone and Mineral Research, 2014, 29, 1981-1992.	3.1	90
18	The Sclerostin-Independent Bone Anabolic Activity of Intermittent PTH Treatment Is Mediated by T-Cellâ€“Produced Wnt10b. Journal of Bone and Mineral Research, 2014, 29, 43-54.	3.1	63

#	Article	IF	Citations
19	Isoformononetin, a methoxydaidzein present in medicinal plants, reverses bone loss in osteopenic rats and exerts bone anabolic action by preventing osteoblast apoptosis. Phytomedicine, 2013, 20, 470-480.	2.3	30
20	Greater Skeletal Gains in Ovary Intact Rats at Maturity Are Achieved by Supplementing a Standardized Extract ofButea monospermaStem Bark that Confers Better Bone Conserving Effect following Ovariectomy and Concurrent Treatment Withdrawal. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-12.	0.5	14
21	Estrogen Deficiency Induces the Differentiation of IL-17 Secreting Th17 Cells: A New Candidate in the Pathogenesis of Osteoporosis. PLoS ONE, 2012, 7, e44552.	1.1	252
22	Formononetin reverses established osteopenia in adult ovariectomized rats. Menopause, 2012, 19, 856-863.	0.8	25
23	Premature T cell senescence in Ovx mice is inhibited by repletion of estrogen and medicarpin: a possible mechanism for alleviating bone loss. Osteoporosis International, 2012, 23, 1151-1161.	1.3	45
24	Bile Acid Receptor Agonist GW4064 Regulates PPARÎ³ Coactivator-1Î± Expression Through Estrogen Receptor-Related Receptor Î±. Molecular Endocrinology, 2011, 25, 922-932.	3.7	30
25	Differential effects of formononetin and cladrin on osteoblast function, peak bone mass achievement and bioavailability in rats. Journal of Nutritional Biochemistry, 2011, 22, 318-327.	1.9	69
26	Daidzein Prevents the Increase in CD4+CD28null T Cells and B Lymphopoesis in Ovariectomized Mice: A Key Mechanism for Anti-Osteoclastogenic Effect. PLoS ONE, 2011, 6, e21216.	1.1	67
27	Extract and fraction from Ulmus wallichiana Planchon promote peak bone achievement and have a nonestrogenic osteoprotective effect. Menopause, 2010, 17, 393-402.	0.8	26
28	Medicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized mice. Molecular and Cellular Endocrinology, 2010, 325, 101-109.	1.6	61
29	Methoxylated isoflavones, cajanin and isoformononetin, have nonâ€estrogenic bone forming effect via differential mitogen activated protein kinase (MAPK) signaling. Journal of Cellular Biochemistry, 2009, 108, 388-399.	1.2	85